ArticleOncotarget2017
Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers.
Giulia Bon et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
8 papers cite it
this papercites it
ArticleOncotarget2017
Giulia Bon et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.